Hazardous drug safety

Learn about the dangers of hazardous drug exposure―they are studied, documented and very real

About 8 million U.S. healthcare workers, including pharmacists, physicians and other caregivers, are potentially exposed to hazardous drugs, according to the CDC.1 This exposure is putting them at risk of both short- and long-term health issues such as headaches, hair loss, nausea, organ damage, reproductive problems,2 developmental impairment, genetic issues and even cancer.3

To address these risks, healthcare facilities need to comply with new and existing standards, guidelines and recommendations. With upcoming changes driven by USP General Chapter <800> Hazardous Drugs—Handling in Healthcare Settings, facilities should use a closed system drug transfer device (CSTD) when compounding hazardous drugs when the dosage form allows, and CSTDs must be used when administering antineoplastic hazardous drugs when the dosage form allows.4

Why BD hazardous drug safety?

When selecting a CSTD solution, you need to protect your team. But we know that is not your only concern. With the BD PhaSeal system, the Texium system and an array of services—all designed to help you reduce the risk of hazardous drug exposure, you can obtain a tailored solution that balances your needs for safety, efficiency and cost.

BD<sup>®</sup> HD Check system

BD® HD Check system

The BD® HD Check system reliably detects hazardous drug contamination on multiple surfaces and locations.

BD PhaSeal<sup>™</sup> system

BD PhaSeal system

The BD PhaSeal system is airtight and leakproof to protect your staff from hazardous drug exposure during drug preparation, administration and disposal.

Texium<sup>™</sup> system

Texium system

Our Texium system is an end-to-end closed system that integrates the drug preparation and delivery process.

Browse all hazardous drug safety products

Browse all hazardous drug safety products

You can view all of our hazardous drug safety products, and search by different selections and criteria.

†Surfaces with contamination at or above the limits of detection have 95% specificity and sensitivity

††For a select number of hazardous drugs: Methotrexate, doxorubicin and cyclophosphamide

 BD-2062 (3/17)

  1. Centers for Disease Control and Prevention (CDC). Hazardous drug exposures in health care. The National Institute for Occupational Safety and Health (NIOSH) Web site. http://www.cdc.gov/niosh/topics/hazdrug. Accessed February 23, 2017.
  2. Connor TH, Lawson CC, Polovich M, McDiarmid MA. Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings: a review of the evidence. J Occup Environ Med. 2014;56(9):901-910.
  3. Hansen J, Olsen JH. Cancer morbidity among Danish female pharmacy technicians. Scand J Work Environ Health. 1994;20(1):22-26.
  4. U.S. Pharmacopeial Convention. <800> Hazardous Drugs—Handling in Healthcare Settings. https://www.usp.org/sites/default/files/usp_pdf/EN/m7808.pdf. Updated December 1, 2014. Accessed February 23, 2017.